Skip to main content

Advertisement

Log in

New arylidene-linked chromane-2,4-dione analogs as potential leads for diabetic management; syntheses, α-amylase inhibitory, and radical scavenging activities

  • Original Paper
  • Published:
Chemical Papers Aims and scope Submit manuscript

Abstract

A range of substituted arylidene chromane-2,4-dione derivatives 1–30 were synthesized by the condensation reaction between 6-chloro-4-hydroxycoumarin and different benzaldehydes in ethanol. All synthesized derivatives are structurally new and fully characterized by various spectroscopic approaches. Compounds were tested for α-amylase inhibitory and radical (DPPH and ABTS) scavenging activities in vitro. When compared to the standard acarbose (IC50 = 12.9 ± 0.1 µM), all derivatives showed significant inhibitory activity against the α-amylase enzyme, with IC50 values ranging from 7.7 ± 0.1 to 60.7 ± 0.1 µM. Compounds were also found to be good radical scavengers of DPPH (IC50 = 21.6 ± 0.2 to 92.1 ± 0.1 µM) and ABTS (IC50 = 22.4 ± 0.1 to 92.7 ± 0.1 µM), compared to standard ascorbic acid (DPPH, IC50 = 14.4 ± 0.1; ABTS, IC50 = 14.9 ± 0.1 µM). Kinetic studies performed on most active molecules revealed competitive-type inhibition mechanisms. The structure–activity relationship (SAR) has been studied to determine the effect of different substitutions of compounds on inhibitory potential. Docking studies of these synthesized coumarin derivatives revealed significant binding interactions with the α-amylase enzyme's catalytic site.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Scheme 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13

Similar content being viewed by others

References

Download references

Acknowledgements

The authors acknowledge the financial support of the Sindh Higher Education Commission (SHEC), Pakistan, vide letter No. NO.DD/SHEC/1-14/2014, Project code SHEC/SRSP/Med-3/15/2021 -21.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Khalid Mohammed Khan.

Ethics declarations

Conflict of interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 3753 KB)

Supplementary file2 (PDF 1892 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Haq, I.u., Ali, I., Khan, K.M. et al. New arylidene-linked chromane-2,4-dione analogs as potential leads for diabetic management; syntheses, α-amylase inhibitory, and radical scavenging activities. Chem. Pap. 77, 2581–2604 (2023). https://doi.org/10.1007/s11696-022-02648-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11696-022-02648-5

Keywords

Navigation